Abstract
ACTIVATED protein C (APC) is a serine protease with potent anti-coagulant properties, which is formed in blood on the endothelium from an inactive precursor1. During normal haemostasis, APC limits clot formation by proteolytic inactivation of factors Va and Villa (ref. 2). To do this efficiently the enzyme needs a non-enzymatic cofactor, protein S (ref. 3). Recently it was found that the anticoagulant response to APC (APC resistance) 4 was very weak in the plasma of 21% of unselected consecutive patients with thrombosis5 and about 50% of selected patients with a personal or family history of thrombosis6,7; moreover, 5% of healthy indi-viduals show APC resistance, which is associated with a sevenfold increase in the risk for deep vein thrombosis5. Here we demonstrate that the phenotype of APC resistance is associated with hetero-zygosity or homozygosity for a single point mutation in the factor V gene (at nucleotide position 1,691, G→A substitution) which predicts the synthesis of a factor V molecule (FV Q506, or FV Leiden) that is not properly inactivated by APC. The allelic fre-quency of the mutation in the Dutch population is ∼2% and is at least tenfold higher than that of all other known genetic risk factors for thrombosis (protein C (ref. 8), protein S (ref. 9), antithrombin10 deficiency) together.
Access options
Subscribe to Journal
Get full journal access for 1 year
$199.00
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
Esmon, C. T. Arteriosclerosis and Thrombosis 12, 135–145 (1992).
- 2
Walker, F. J. & Fay P. J. FASEB J. 6, 2561–2567 (1992).
- 3
Walker, F. J. J. biol. chem. 255, 5521–5524 (1980).
- 4
Dahlbäck, B., Carlsson, M. & Svensson, P. J. Proc. natn. Acad. Sci. U.S.A. 90, 1004–1008 (1993).
- 5
Koster, T. et al. Lancet 342, 1503–1506 (1993).
- 6
Svensson, P. J. & Dahlbäck, B. New Engl. J. Med. 300, 517–522 (1994).
- 7
Griffin, J. H., Evatt, B., Wideman, C. & Fernandez, J. A. Blood 82, 1989–1993 (1993).
- 8
Allaart, C. F. et al. Lancet 341, 134–138 (1993).
- 9
Engesser, L., Broekmans, A. W., Briët, E., Brommer, E. J. P. & Bertina, R. M. Ann. int. Med. 106, 677–682 (1987).
- 10
Hirsh, J., Piovella, F. & Pini, M. Am. J. Med. 87, 345–385 (1989).
- 11
Dahlbäck, B & Hildebrand, B. Proc. natn. Acad. Sci. U.S.A. 91, 1396–1400 (1994).
- 12
Wang, H., Riddell, D. C., Quinto, E. R., MacGillivray, R. T. A. & Hamerton, J. L. Genomics 2, 324–328 (1988).
- 13
Jenny, R. J. et al. Proc. natn. Acad. Sci. U.S.A. 84, 4846–4850 (1987).
- 14
Kane, W. H. & Davie, E. W. Proc. natn. Acad. Sci. U.S.A. 83, 6800–6804 (1986).
- 15
Kane, W. H., Ichinose, A., Hagen, F. S. & Davie, E. W. Biochemistry 26, 6508–6514 (1987).
- 16
Cripe, L. D., Moor, K. D. & Kane, W. H. Biochemistry 31, 3777–3785 (1992).
- 17
Shen, N. L. L. et al. J. Immun. 150, 2992–3001 (1993).
- 18
Walker, F. J., Scandella, D. & Fay, P. J. J. biol. Chem. 265, 1484–1489 (1990).
- 19
Walker, F. J. & Fay, P. J. J. biol. Chem. 265, 1834–1836 (1990).
- 20
Odegaard, B. & Mann, K. J. biol. Chem. 262, 11233–11238 (1987).
- 21
Suzuki, K., Dahlbäck, B & Stenflo, J. J. biol. Chem. 257, 6556–6564 (1982).
- 22
Monkovic, D. D. & Tracey, P. B. Biochemistry 29, 1118–1128 (1990).
- 23
Yang, X. J. et al. Biochem. J. 272, 399–406 (1990).
- 24
Triglia, T., Peterson, M. G. & Kemp, D. J. Nucleic Acids Res. 16, 8186 (1988).
- 25
NIH/CEPH Collaborative Mapping Group Science 258, 67–86 (1992).
- 26
Guinto E. R., Esmon C. T., Mann K. G. & MacGillivray R. T. A. J. biol. Chem. 267, 2971–2978 (1992).
- 27
Pieters, J. & Lindhout, T. Blood 72, 2048–2052 (1988).
- 28
Chromczynski, P. & Sacchi, N. Analyt. Biochem. 162, 156–159 (1987).
- 29
Reitsma, P. H., Poort, S. R., Allaart, C. F., Briëf, E. & Bertina, R. M. Blood 78, 890–984 (1991).
- 30
Verduyn, W. et al. Hum. Immun. 37, 59–67 (1993).
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Bertina, R., Koeleman, B., Koster, T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64–67 (1994). https://doi.org/10.1038/369064a0
Received:
Accepted:
Issue Date:
Further reading
-
Molecular Insights and Functional Consequences of the Interaction of Heme with Activated Protein C
Antioxidants & Redox Signaling (2021)
-
Biomedical applications of snake venom: from basic science to autoimmunity and rheumatology
Journal of Translational Autoimmunity (2021)
-
Rare variants in MTHFR predispose to occurrence and recurrence of pulmonary embolism
International Journal of Cardiology (2021)
-
Education Case: Hereditary Thrombophilia With Double Heterozygous Factor V Leiden and Factor II c.*97G>A Mutations
Academic Pathology (2021)
-
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis
Thrombosis Research (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.